In the matter of the Patent Act RSC 1985, c P-4, as amended and in the matter of Sandoz Canada Inc

Counsel to Board Staff at the Patented Medicines Prices Review Board, in matter involving questions of whether generic subsidiaries of innovator drug companies should be required to report pricing information to the Board. Decision appealed by Sandoz and upheld by FCA. (Prior to joining Lenczner Slaght)